Hepatocyte cholesterol content modulates glucagon receptor signalling

Emma Rose McGlone 1,2, T. Bertie Ansell 3, Cecilia Dunsterville 4, Wanling Song 4,6, David Carling 4, Alejandra Tomas 1, Stephen R. Bloom 1, Mark S.P. Sansom 4,7, Tricia Tan 1, Ben Jones 1,4,

STRUCTURED ABSTRACT

Objective: To determine whether glucagon receptor (GCGR) actions are modulated by cellular cholesterol levels.

Methods: We determined the effects of experimental cholesterol depletion and loading on glucagon-mediated cAMP production, ligand internalisation and glucose production in human hepatoma cells, mouse and human hepatocytes. GCGR interactions with lipid bilayers were explored using coarse-grained molecular dynamic simulations. Glucagon responsiveness was measured in mice fed a high cholesterol diet with or without simvastatin to modulate hepatocyte cholesterol content.

Results: GCGR cAMP signalling was reduced by higher cholesterol levels across different cellular models. Ex vivo glucagon-induced glucose output from mouse hepatocytes was enhanced by simvastatin treatment. Mice fed a high cholesterol diet had increased hepatic cholesterol and a blunted hyperglycaemic response to glucagon, both of which were partially reversed by simvastatin. Simulations identified likely membrane-exposed cholesterol binding sites on the GCGR, including a site where cholesterol is a putative negative allosteric modulator.

Conclusions: Our results indicate that cellular cholesterol content influences glucagon sensitivity and indicate a potential molecular basis for this phenomenon. This could be relevant to the pathogenesis of non-alcoholic fatty liver disease, which is associated with both hepatic cholesterol accumulation and glucagon resistance.

Keywords Glucagon; Glucagon receptor; Cholesterol; Cell membrane; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus

1. INTRODUCTION

Glucagon is a key regulator of hepatic metabolism: as well as increasing glucose production to counteract hypoglycaemia, it reduces liver fat by decreasing de novo lipogenesis and increasing fatty acid oxidation [1,2]. Individuals with type 2 diabetes mellitus (T2D) and/or non-alcoholic fatty liver disease (NAFLD) exhibit hepatic glucagon resistance [3,4], which in turn contributes to worsening of steatosis by blocking the beneficial effects of glucagon on hepatic fat. To date, the mechanism behind this phenomenon is incompletely understood [5]. Hepatic cholesterol accumulation is a feature of NAFLD and, interestingly, the degree of both glucagon resistance [6] and hepatic cholesterol accumulation [7,8] are correlated with histological severity of the disease.

The glucagon receptor (GCGR) is a prototypical class B G protein-coupled receptor (GPCR). It is increasingly appreciated that the functions of cell surface GPCRs are heavily modulated by other membrane components [9], including lipids [10]. This can occur either through direct lipid—receptor interactions [11], or indirectly, e.g. by altering the properties of the membrane bilayer [12]. Cholesterol is known to alter the conformation of some GPCRs by directly binding to allosteric sites [13,14]; it is also a key structural component of the plasma membrane that controls the distribution and spatial coupling between surface receptors and intracellular mediators [15]. We have recently demonstrated that cholesterol depletion affects signalling and endomembrane trafficking of the closely related glucagon-like peptide 1 receptor (GLP-1R) [16]. To date, the relevance of cellular cholesterol to GCGR signalling has not been explored experimentally.

1Department of Metabolism, Digestion and Reproduction, Imperial College London, London W12 ONN, United Kingdom 2Department of Surgery and Cancer, Imperial College London, London W12 ONN, United Kingdom 3Department of Biochemistry, University of Oxford, Oxford OX1 3QU, United Kingdom 4Cellular Stress Research Group, MRC London Institute of Medical Sciences, Imperial College London, London W12 ONN, United Kingdom

5 Current address: Rahko, Clifton House, 46 Clifton Terrace, Finsbury Park, London N4 3JP, United Kingdom.

*Corresponding author.

**Corresponding author.

E-mails: e.mcggone@imperial.ac.uk (E.R. McGlone), bertie.anSELL@bioch.ox.ac.uk (T.B. AnSELL), c.dunsterville19@imperial.ac.uk (C. Dunsterville), wanling.song@bioch.ox.ac.uk (W. Song), david.carling@lms.mrc.ac.uk (D. Carling), s.tomas-catala@imperial.ac.uk (A. Tomas), s.bloom@imperial.ac.uk (S.R. Bloom), mark.sansom@bioch.ox.ac.uk (M.S.P. Sansom), t.tane@imperial.ac.uk (T. Tan), b.jones@imperial.ac.uk (B. Jones).

Abbreviations: GCGR, glucagon receptor; T2D, type 2 diabetes mellitus; NAFLD, non-alcoholic fatty liver disease; GPCR, G protein-coupled receptor; GLP-1R, glucagon-like peptide 1 receptor; MI, C0D, methyl-β-cyclodextrin; MD, molecular dynamics

Received June 13, 2022 • Accepted June 13, 2022 • Available online 16 June 2022

https://doi.org/10.1016/j.molmet.2022.101530
The aim of this study was to investigate whether hepatocyte cholesterol content affects GCGR signalling and its downstream physiological correlates. We demonstrate that enrichment of cholesterol in vitro and in vivo decreases glucagon responsiveness, whereas cholesterol depletion has the opposite effect. Molecular dynamics (MD) simulations identify likely cholesterol binding sites on the GCGR which may allosterically regulate its function. Our results indicate that hepatocyte cholesterol content influences hepatic glucagon sensitivity and pinpoint a potential molecular basis for this phenomenon.

2. MATERIALS AND METHODS

2.1. Cell culture and primary hepatocyte isolation
Huh7-GCGR cells [17] were cultured at 37 °C in 5% CO₂ in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin, with 1% G418 for the latter (Thermo Fisher). Hepatocytes from male adult C57BL/6J mice were isolated using collagenase perfusion, as previously described [18], and were either assayed in suspension or plated and cultured at 37 °C, 5% CO₂ in M199 supplemented with 1% penicillin/streptomycin, 1% BSA, 2% Ultroser G, 100 nM T3, 100 nM dexamethasone and 100 nM insulin (Thermo Fisher). After 5 h, medium was changed to M199 with 1% penicillin/streptomycin, 100 nM dexamethasone and 10 nM insulin for serum starvation. Primary hepatocytes from human cadaveric donors were obtained from Biopredic International (St Gregoire, France) and assayed in suspension. Donor characteristics are listed in Supplementary Table 1.

2.2. Peptides
Glucagon and a fluorescent glucagon analogue, “FITC-GCG” [glucagon (1–29) with a C-terminal extension Gly30,31Lys32-FITC (fluorescein isothiocyanate)], which has similar potency for cAMP as the native ligand [17], were obtained from Wuxi Apptec.

2.3. Cholesterol-modulating treatments
Cells were treated with cholesterol-saturated methyl-β-cyclodextrin (Sigma–Aldrich; referred to as “cholesterol” hereafter when in the context of cellular treatments; 50 μg/ml unless otherwise stated), or cholesterol-depleted methyl-β-cyclodextrin (Sigma–Aldrich; MβCD; 3 mM unless otherwise stated), in Hank’s buffered saline solution (HBSS) for 30 min. Plated cells were treated with 10 μM simvastatin (Sigma–Aldrich) and/or 50 μM mevalonate (Sigma–Aldrich) for 16 h in serum-free medium. All treatments were washed off prior to experiments. Cell toxicity following treatments was measured using MTT Cell Viability Assay (Thermo Fisher), as per manufacturer’s instructions.

2.4. cAMP accumulation
Huh7-GCGR cells plated in 96-well plates, or primary mouse or human hepatocytes in suspension, were stimulated with agonist in serum-free medium for 10 min at 37 °C. Cells were lysed, and cAMP was assayed by immunooassay (Cisbio HTRF cAMP Dynamic 2). For further details see Supplementary Methods.

2.5. cAMP detection by live cell imaging
Huh7-GCGR cells were transduced with cADDis biosensors [19] (Montana Molecular) in a BacMam vector; for further details see Supplementary Methods.

2.6. PKA activation assay
PKA activation was assessed in Huh7-GCGR cells by FRET imaging using AKAR4-NES [20] (gift from Jin Zhang, Addgene plasmid # 64,727); for further details see Supplementary Methods.

2.7. Mini-G NanoBRET assay
Recruitment of Mini-Gα and mini-Gβ was assessed in Huh7-GCGR cells transfected with Mini-G constructs tagged with nanoluciferase [21] (a gift from Prof Nevin Lambert, Medical College of Georgia) and the membrane marker KRAS-venus; for further details see Supplementary Methods.

2.8. Molecular dynamics simulations, analysis and computational binding saturation curves
Structures of the GCGR in inactive and active conformations were derived from the Protein Data Bank (PDB ID: inactive 5XEZ, active 6LMK) [22,23]. Please see Supplementary Methods.

2.9. Hepatocyte glucose output assay
Primary mouse hepatocytes were serum-starved overnight with the addition of simvastatin 10 μM or vehicle (DMSO). After washing, phenol-red free DMEM with 1 mM sodium pyruvate (Gibco) and 20 mM sodium lactate (Sigma) was added. Baseline samples were taken before addition of glucagon 100 nM or vehicle, and following incubation at 37 °C for 24 h. Glucose was assayed using a glucose oxidase assay (Randox), normalised to protein content of the well (BCA assay, Thermo Fisher), and expressed as fold change of glucose production in the absence of glucagon.

2.10. Animals and dietary manipulation
Experiments were performed in accordance with the UK Animals (Scientific Procedures) Act 1986 and approved by the Animal Welfare and Ethical Review Board at Imperial College London. C57BL/6J male mice (Charles River) were group-housed in a pathogen-free facility at controlled temperature (22 °C) with a 12-hour light dark cycle. Access to food was ad libitum, except prior to fasting studies, and mice always had free access to water. Mice were fed standard chow (SDS Rm3) during acclimatisation. Specialist chows were based on a standard Clinton/ Cybulsky rodent diet (10% kcal from fat and 70% kcal from carbohydrate) and were identical in constitution and calorie content, except for 0% (Control) or 0.5% added cholesterol (Chol), or 0.5% cholesterol and 120 mg/kg simvastatin (Chol/simv) (Research Diets). Mice were fed specialist diets for 7–9 days before glucagon challenge test and 12 days before the cull, via decapitation following a 5-hour fast. The liver was harvested, snap frozen in liquid nitrogen and stored at −80 °C.

2.11. Glucagon challenge test
Glucagon challenge tests were performed in the light phase, in mice fasted for 5 h [24,25]. Tail vein blood glucose was measured using a glucometer (Nexus, GlucoRx) before and at intervals following intraperitoneal injection with 2 g/kg sodium pyruvate (Sigma) as a glucoseogenic substrate ± 10 mmol/kg glucagon. Each mouse underwent the test with and without glucagon, in a random order, with an intervening washout period of 3 days.

2.12. Lipid extraction
Lipids were extracted from liver tissue by homogenization in ethanol (0.03x v/v) [26], and from cells by agitation in butanol, before evaporation and resuspension in methanol.

2.13. Biochemical assays
Liver triglyceride was measured using a GPO-PAP Triglyceride assay (Randomo) and cholesterol using Amplex Red Cholesterol Assay Kit (Thermo Fisher). Serum glucagon and alanine were measured using commercial kits available from Cisbio and Sigma–Aldrich respectively.
2.1.4. Statistical analyses
All statistical analysis of experimental data was performed using Prism 9.2.0 for macOS (Graphpad Software, San Diego, California USA). Concentration-response curves were generated by 3-parameter logistic fitting or using a “bell-shaped” fit. For cAMP, $E_{\text{max}}$ and log$_{10}$-transformed EC$_{50}$ values were derived for each repeat and then compared using t-tests or one-way ANOVA, with matched analyses performed where permitted by experimental design, and multiple comparison tests as indicated in the figure legends. For experiments using pertussis toxin, the G$_a$ component of the bell-shaped response was calculated by subtracting response in the presence of pertussis toxin (i.e. the G$_b$-specific response) from total response. For cellular treatments, as a combined measure of agonism, $E_{\text{max}}$/EC$_{50}$ was calculated and normalised to vehicle control; log$_{10}$-transformed values were then used for simple linear regression analysis, with calculation of goodness of fit. Glucagon-alanine index was calculated by multiplying fasting levels of glucagon (pmol/l) with alanine (mmol/l) [27]. p < 0.05 was considered statistically significant.

3. RESULTS
3.1. Acute manipulation of cellular cholesterol content modulates GCGR signalling
We first examined the impact of pharmacological modulation of cellular cholesterol levels on GCGR signalling in Huh7 hepatoma cells. GCGR was exogenously expressed due to undetectable endogenous levels [17]. At picomolar concentrations of glucagon, cAMP signalling was enhanced by pre-treatment with cholesterol-free methyl-$\beta$-cyclodextrin (M$\beta$CD), which rapidly extracts cholesterol from cellular membranes, whereas cholesterol loading with cholesterol-saturated M$\beta$CD had the opposite effect (Figure 1A; Supplementary Table 2). M$\beta$CD was not toxic to cells (Supplementary Figure 1A). GCGR shows a hormetic (bell-shaped) cAMP concentration-relationship due to superimposed effects of G$_a$-mediated stimulation and G$_b$-mediated inhibition of cAMP production [28], so we investigated the effects of modifying cellular cholesterol content on the G$_a$ and G$_b$ components of the overall cAMP response over a wide glucagon concentration range using the G$_b$ inhibitor pertussis toxin [29] (Figure 1B). The G$_a$ response required at least 10-fold more glucagon than the G$_b$ response (Supplementary Table 1) but became dominant at higher concentrations. We found that both G$_a$- and G$_b$-mediated control of cAMP levels were increased by cholesterol depletion, and diminished by cholesterol loading, such that the overall balance between each component was not significantly altered (Figure 1C).

Given these opposing effects of G$_a$ and G$_b$ on GCGR signalling, we decided to investigate cAMP dynamics in Huh7-GCGR cells using a fluorescent biosensor, cADDis [19], which reports changes in intracellular cAMP in real time. At a supra-maximal glucagon concentration (100 nM; Figure 1D) a rapid peak in cAMP levels was followed by a steady reduction, whilst a much lower concentration (50 pM; Figure 1E) led to a sustained increase. Moreover, the effects of cholesterol manipulation on these responses were different at low and high glucagon concentrations, e.g. cholesterol depletion using M$\beta$CD increased the cAMP response at 50 pM but reduced it at 100 nM. This pattern is consistent with the net effect of M$\beta$CD reflecting the concentration-specific “dominant” G$_b$ subtype response (i.e. G$_a$ at lower concentrations, G$_b$ at higher concentrations).

Membrane lipid composition is a key factor dictating how GPCRs and their intracellular effectors are concentrated into signalling nano-domains [16]. We therefore aimed to determine whether membrane cholesterol manipulation could alter the localisation of cAMP production in Huh7-GCGR cells using cADDis sensors targeted either to “raft” or “non-raft” membrane regions (Figure 1F). Whilst membrane cAMP production at 50 pM glucagon tended to be increased with M$\beta$CD and reduced with cholesterol loading, as was the case for total cellular cAMP, we did not find any difference between responses measured in each membrane sub-domain (Figure 1F). As a key mediator of GCGR-mediated liver effects downstream of cAMP [3], we also recorded cytosolic protein kinase A (PKA) activation using the FRET biosensor AKAR4 [30] (Figure 1G). The effects of cholesterol manipulation on PKA response potencies agreed with the pattern seen for cAMP (Supplementary Table 2).

GCGR ligand internalisation represents an additional downstream functional readout of GCGR activation. We examined this phenomenon in Huh7-GCGR cells following treatment with cholesterol-lowering-or -enriching agents using fluorescein isothiocyanate-tagged glucagon (“FITC-GCG”), which closely mimics the pharmacology of native glucagon and has previously been used to study GCGR trafficking effects [17]. Interestingly, and in contrast to the effects on cAMP signalling, we observed an increase in FITC-GCG uptake after cholesterol loading, and a decrease after cholesterol depletion (Supplementary Figure 1B, 1C, Supplementary Table 1).

We next corroborated some of these findings using primary human hepatocytes from cadaveric donors (Figure 1H; Supplementary Table 2 for donor characteristics). Cholesterol depletion at increasing concentrations of M$\beta$CD progressively increased potency but reduced $E_{\text{max}}$ for glucagon-induced cAMP, with cholesterol loading showing the opposite pattern (Figure 1I). cAMP signalling potency was also reduced by cholesterol loading in primary mouse hepatocytes (Figure 1J). Whilst the pronounced bell-shaped concentration-response relationship from Huh7-GCGR cells was not observed in either primary cell type, possibly as the phosphodiesterase inhibitor IBMX used in the primary hepatocyte assays promotes cAMP accumulation and would therefore reduce G$_b$-dependent cAMP suppression, the pattern can again be explained by cholesterol levels influencing G$_a$-dominant effects at low glucagon concentrations and G$_b$ effects at higher glucagon concentrations. Although we did not measure it in our study, it is important to note that G$_b$-dependent GCGR signalling effects extend beyond the suppression of cAMP production, for example leading to increases in c-Jun kinase (JNK) phosphorylation, a process which is implicated in GCGR-mediated hepatic glucose output [25].

3.2. Sustained cholesterol depletion using statins increases glucagon-induced hepatic glucose output
To investigate the potential for sustained reduction in cellular cholesterol to modulate GCGR signalling and establish a basis for how this might be relevant pharmacologically, we pre-treated Huh7-GCGR cells with the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR) inhibitor simvastatin to inhibit cholesterol synthesis. There was no cell toxicity with simvastatin treatment (Supplementary Figure 2A). Like M$\beta$CD-mediated acute cholesterol depletion, simvastatin also increased glucagon cAMP potency (Figure 2A, Supplementary Table 3); notably, this effect was reversed by supplementing cells with the HMGR enzyme product mevalonate (which is otherwise depleted by statins), and also by acute restoration of membrane cholesterol levels using cholesterol-saturated M$\beta$CD (Figure 2A, Supplementary Table 3). There was a robust inverse correlation between relative cellular cholesterol content and cAMP responses from these assays and those presented in Figure 1A (see Figure 2B), whereas the opposite correlation was seen between cellular cholesterol and FITC-GCG uptake (Supplementary Figure 2B, 2C). In line with the effect of M$\beta$CD, both
Gαs and Gαi cAMP responses were similarly augmented by simvastatin (Supplementary Figure 2D, 2E).

We also asked whether simvastatin could influence how hepatocytes respond to sustained periods of glucagon elevation, such as during fasting or with pharmacological GCGR agonism. After overnight stimulation with glucagon, inspection of steady state cAMP levels in Huh7-GCGR cells again suggested that both Gαs- and Gαi-dependent GCGR signalling are potentiated by simvastatin, as the entire bell-shaped concentration-response curve was shifted to the left (Figure 2C, Supplementary Table 3). Moreover, glucagon-induced glucose output from primary mouse hepatocytes was increased by simvastatin treatment (Figure 2D).

Figure 1: Acute changes in cellular cholesterol levels influence glucagon-stimulated cAMP production in a concentration-dependent manner (A) cAMP concentration-response curves in Huh7-GCGR cells pre-treated with cholesterol-deplete MβCD at indicated concentrations or cholesterol-saturated MβCD (Chol), then stimulated with glucagon (GCG), n = 4. (B) cAMP responses over a wider glucagon concentration range with or without pertussis toxin pre-treatment (PTX; 10 ng/ml) to block Gαi-mediated cAMP inhibition and reveal the Gαs- and Gαi-specific responses, n = 6. The effect of pre-treatment with MβCD or cholesterol is shown. (C) Balance between Gαs and Gαi-mediated cAMP effects from (B); all inter-group statistical comparisons non-significant by one-way repeated measures ANOVA. (D) cAMP dynamics measured in Huh7-GCGR cells transduced with cADDis sensor (pictured; scale bar = 80 μm) pre-treated with MβCD or cholesterol and stimulated with 100 nM glucagon. Representative images from cells at baseline, 5 min after glucagon stimulation, and 5 min after addition of 100 μM IBMX and 10 μM forskolin (FSK). AUC comparison by one-way repeated measures ANOVA with Tukey’s test, n = 8. (E) As for (D) but 50 pM glucagon, n = 9. (F) As for (D) but using membrane-targeted cADDis cAMP sensors as indicated, n = 7. (G) PKA activation in Huh7-GCGR cells expressing AKAR4-NES and pre-treated with MβCD or cholesterol. Representative FRET images of same cells at baseline, 5 min after glucagon stimulation, and 5 min after addition of 100 μM IBMX and 10 μM forskolin (FSK); scale bar 40 μm, n = 5. (H) cAMP accumulation in primary cadaveric human hepatocytes, 10 min stimulation with 100 μM IBMX, n = 4. The two panels are from the same experiments and separated for clarity. (I) Quantification of signalling potency and maximum responses from (H) in relationship to cholesterol modulating treatments, with one-way repeated measures ANOVA and linear test for trend. (J) cAMP accumulation in primary mouse hepatocytes, 10 min stimulation with 100 μM IBMX, n = 5. *p < 0.05, **p < 0.01, ***p < 0.001. Data are shown as mean ± SEM, with individual experimental replicates where possible.

Gαs and Gαi cAMP responses were similarly augmented by simvastatin (Supplementary Figure 2D, 2E).

We also asked whether simvastatin could influence how hepatocytes respond to sustained periods of glucagon elevation, such as during fasting or with pharmacological GCGR agonism. After overnight stimulation with glucagon, inspection of steady state cAMP levels in Huh7-GCGR cells again suggested that both Gαs- and Gαi-dependent GCGR signalling are potentiated by simvastatin, as the entire bell-shaped concentration-response curve was shifted to the left (Figure 2C, Supplementary Table 3). Moreover, glucagon-induced glucose output from primary mouse hepatocytes was increased by simvastatin treatment (Figure 2D).
Overall, these data indicate that acute and sustained changes to cellular cholesterol levels in vitro can bidirectionally affect GCGR cAMP signalling, trafficking, and downstream effects.

3.3 Molecular dynamics simulations reveal potential GCGR-cholesterol binding sites

To explore the potential for direct interactions between the GCGR and cholesterol in the plasma membrane as an underlying mechanism for our pharmacological observations, we performed coarse-grained MD simulations of full-length GCGR within bilayers in active and inactive states. A single receptor molecule was simulated whilst embedded in plasma membrane mimetic bilayers containing 25% cholesterol. The locations of predicted cholesterol binding sites with the four highest cholesterol residence times were the same for the two GCGR conformations (Figure 3A, B, Supplementary Video 1). These correspond to a binding site between helices TM1 and TM2 (site-1), the extracellular portion of TM3/TM4 (site-2), an intracellular site formed by TM5, ICL3 and TM6 (site-3), and a densely packed site at the centre of TM6/TM7 (site-4). We note that for site-1, in the inactive GCGR conformation interacting residues were diffuse (Figure 3A), whereas in the active conformation they were restricted to the extracellular region (Figure 3B). The residues involved in formation of other sites were in broad supplementary video related to this article can be found at https://doi.org/10.1016/j.molmet.2022.101530

For the active GCGR conformation, cholesterol binding sites in proximity to TM5/TM6 (site-3 and site-4) were stabilised and site-2 interactions were destabilised when compared to the inactive conformation. These findings indicate that, whilst the location of key cholesterol binding sites is comparable between full-length GCGR conformations, receptor activation induces subtle changes in cholesterol kinetics that result in more prolonged residence times around TM5, ICL3, TM6 and TM7. Surprisingly, the top ranked cholesterol pose at site-4 from the coarse-grained simulations was oriented with the β3-hydroxyl group at the bilayer midplane (i.e. flipped by 180° compared to the anticipated cholesterol orientation based on that within the bilayer) (Figure 3C). To examine this further we performed microsecond atomistic simulations of the site-4 cholesterol which remained stably bound for the majority of the trajectories (Figure 3D, blue), in agreement with the predicted residence time from coarse-grained simulations (0.8 μs). In contrast, control simulations initiated with cholesterol bound in the reverse (conventional, i.e. β3-hydroxyl group towards the bilayer/water interface) orientation at site-4 led to rapid cholesterol dissociation (<0.2 μs) (Figure 3D, grey). We attribute the stability of this unusual cholesterol pose at site-4 to H-bonding interactions between the cholesterol hydroxyl group and S390/Q392 on TM7 and due to F387 which folds over the top of the cholesterol molecule, effectively shielding the β3-hydroxy group from the surrounding hydrophobic membrane environment (Figure 3C).

To further evaluate the relevance of identified sites we performed simulations using membrane bilayers with varying cholesterol content [31] which allowed us to estimate apparent dissociation constants for cholesterol at each site (Figure 3E; Kapp at site-1: 10.7 ± 0.3%; site-2: 18.3 ± 0.4%; site-3: 15.0 ± 0.8%; and site-4: 6.6 ± 0.1%. The site-4 Kapp was comparable to ‘strong’ cholesterol binding sites observed on various other membrane proteins e.g. on the TRP channel Polycystin-2 (11 ± 1%), on Patched1 (6.8 ± 0.3%) and on the GPCR 5-HT1A (4 ± 9%) where cholesterol densities have been observed in structures and cholesterol is implicated in biological function [31]. While interpreting the relative specificity of cholesterol sites from kinetics alone can be challenging, saturable binding curves were observed which were distinct from background non-specific interactions (Figure 3E, black line). Thus, predicted affinities for cholesterol interactions with GCGR were comparable to those for ‘strong’ cholesterol sites on other proteins, which in turn correlates with the results of our biochemical experiments.

Site-3 overlaps with the experimentally verified G protein binding site for GCGR and other class B GPCRs [23,32], and site-4 corresponds to TM6, which tilts outwards during receptor activation to accommodate G protein binding. In view of the inverse correlation between membrane cholesterol content and cAMP signalling (Figure 2B), we hypothesised that cholesterol could act as a negative allosteric regulator at sites-3/4 [33] by reducing the capacity of the receptor to interact with Gαs. We investigated this possibility by measuring recruitment of mini-Gαs, a conformational biosensor for Gαs-favouring active GPCR conformations [34], and found that cholesterol loading reduced glucagon-stimulated mini-Gαs recruitment to plasma membrane GCGR in Huh7-GCGR cells (Figure 3F). Whilst the ligand-induced mini-Gαs recruitment response was much smaller than for mini-Gαs, as previously shown in HEK293 cells [35], this was also reduced by cholesterol loading (Figure 3G). These observations are in line with our cAMP data in Figure 1B indicating the PTX-sensitive and insensitive elements of the GCGR cAMP response are both suppressed by cholesterol enrichment.

Figure 2: Simvastatin treatment enhances glucagon-stimulated signalling and glucose output. (A) The effect on glucagon-stimulated cAMP production (10 min) in Huh7-GCGR cells pre-treated with simvastatin (Simva) or serum-free medium (SFM) overnight, with concurrent or subsequent treatment with or without mevalonate (mev; 50 μM) or cholesterol-saturated MβCD (chol; 50 μg/ml). Results are normalized to forskolin (FSK; 10 μM), n = 5. (B) Association between a combined measure of cAMP efficacy and potency (log-transformed Emax/EC50) and cellular cholesterol for each of the treatments shown in Figure 1A and Figure 2A, both normalized to vehicle control, with linear regression line ± 95% confidence intervals shown. (C) Steady state cAMP concentrations in Huh7-GCGR cells co-treated with glucagon and simvastatin/vehicle for 16 h, with normalisation to the acute 10 μM FSK response taken at the end of the incubation, n = 5. (D) Glucose production in primary mouse hepatocytes pre-treated with simvastatin or vehicle overnight, then stimulated with glucagon for 24 h, expressed as fold change over no-glucagon control stimulation, n = 7, with paired t-test. Data are shown as mean ± SEM, with individual experimental replicates in (D).
after 5 h of fasting, at which point both glycogenolysis and
We performed an intra-peritoneal glucagon/pyruvate challenge test
abrogated in mice also fed simvastatin.
index than control mice (Figure 4E, F). Notably, these changes were
high cholesterol diet had higher fasting alanine and glucagon-alanine
bound for amino acid catabolism [27,38], and found that mice fed
measured fasting alanine in a subset of mice, which is expected to be
high when glucagon receptor signalling is impaired due to the role of
increasing hepatic cholesterol in mice decreases glucagon
sensitivity
To explore the potential relevance of these findings in vivo, we next
manipulated hepatic cholesterol in adult mice using isocaloric chow
supplemented with or without 0.5% cholesterol (cho! with or without
simvastatin (cho!/simva). Whilst these diets had no effect on body
weight or hepatic triglyceride content (Figure 4A, B), the cholesterol-
enriched diet caused a dramatic increase in hepatic cholesterol after
1 week, which was partially abrogated by simvastatin (Figure 4C).
Although fasting glucagon was comparable between groups (control:
9.2 ± 1.9 pmol/L; cho! 12.0 ± 1.9 pmol/L; cho!/simva
16.1 ± 2.6 pmol/L, ns by one-way ANOVA with Tukey’s test), mice fed
a high cholesterol diet had a lower fasting plasma glucose, consistent
with reduced glucagon signalling [36,37] (Figure 4D). We also
measured fasting alanine in a subset of mice, which is expected to be
high when glucagon receptor signalling is impaired due to the role of
glucagon in amino acid catabolism [27,38], and found that mice fed
high cholesterol diet had higher fasting alanine and glucagon-alanine
index than control mice (Figure 4E, F). Notably, these changes were
abrogated in mice also fed simvastatin.
We performed an intra-peritoneal glucagon/pyruvate challenge test
after 5 h of fasting, at which point both glycogenolysis and
4. DISCUSSION
In this study we demonstrate an inverse relationship between hepato-
cytes and glucagon responsiveness, as measured in vitro
by glucagon-stimulated CAMP and glucose production, and in vivo
from fasting metabolic parameters and the hyperglycaemic response to
exogenous glucagon. Further, we have identified probable cholesterol
binding sites on GCGR that could mediate these effects.
To our knowledge this is the first time the effect of cholesterol on GCGR
function has been reported. Increasing membrane cholesterol en-
chances the function of some GPCRs, e.g. the α1A-adrenergic receptor,

Figure 3: Predicted GCGR-cholesterol interactions. The top four ranked binding sites for cholesterol from coarse-grained MD simulations of the glucagon receptor (GCGR) in
inactive (A) and active (B) conformations in plasma membrane-like bilayers containing 25% cholesterol. Each conformation was simulated for 10 × 10 μs. Distinct binding sites
are coloured yellow (site-1), red (site-2), lilac (site-3) and blue (site-4). Residues comprising each site are shown as spheres scaled by per residue cholesterol residence times. The
residence time for cholesterol binding to each site is indicated. Binding sites and associated residence times were calculated using PyLipID [43]. (C) Snapshot from atomistic
simulations of the top ranked cholesterol binding pose at site-4, as identified by PyLipID from the coarse-grained simulations. GCGR is shown in surface representation and
cholesterol is shown as sticks. F387 is coloured blue and encloses a pocket which shields the cholesterol hydroxyl group from the membrane (see inset for coordinating residues of
TM7). (D) Minimum distance between the site-4 cholesterol and L395 (a key residue in site-4) across atomistic simulations. Simulations were initiated from the top ranked
cholesterol pose whereby the hydroxy group was located towards the center of the bilayer (3 × 1 μs, blue) or with the cholesterol reversed by 180° such that the hydroxy group
was in proximity to the lipid phosphate groups (3 × 500 ns, grey). (E) Binding saturation curves for cholesterol binding to each site from equilibrium MD simulations (5 × 5 μs at
each % free cholesterol). Site % occupancy was calculated using PyLipID and plotted against the free cholesterol % (see methods) in binary bilayers composed of POPC and
cholesterol. (F) BRET signal (535/460) indicating interaction between nanoluciferase-tagged mini-Gi and GCGR in the plasma membrane in Huh7-GCGR cells expressing Kras-
genesis, 30 min after stimulation with vehicle or 100 nM glucagon, n = 7, compared by two-way repeated measures ANOVA with Sidak’s test. (G) As for (F) but using mini-Gi,
*p < 0.05, ***p < 0.001. Data are shown as mean ± SEM, with individual experimental replicates in Figure 2F, G.
and diminishes that of others, e.g. the cannabinoid receptor 1 and β₁-adrenergic receptor [33,39]. We previously showed that cholesterol depletion in pancreatic beta cells led to reductions in both cAMP signalling and ligand-induced endocytosis of the closely related GLP-1R [16]. This partly contrasts with our current GCGR results, in which cholesterol depletion reduced uptake of fluorescent glucagon, but enhanced potency for GCGR-dependent cAMP production. The discrepancy may reflect inherent differences in the effect of cholesterol on the two receptors, though it is worth noting that GPCR function is also modulated by concomitantly-interacting membrane proteins, e.g. Receptor Activity Modifying Protein 2 (RAMP2) [17], and other membrane constituents that differ depending on cell type, which could in turn impact the role played by cholesterol. Other class B GPCRs for which the impact of cholesterol manipulation have been studied are summarised in Supplementary Table 4.

Somewhat peculiar to GCGR signalling are the superimposed and opposing effects of Gαs and Gαi on cAMP production, which led to a pronounced bell-shaped concentration—response relationship for cAMP. As the Gα subtype “preference” varied across the glucagon concentration range, and both components were increased when cholesterol was depleted or decreased on cholesterol loading, the net effect of cholesterol manipulation on cAMP production was concentration-specific. It is important to note that, even though cAMP is a useful indicator of how GCGR function can be affected by cholesterol, the impact on downstream readouts may not show the same homeric relationship. For example, 100 nM glucagon caused marked suppression of cAMP production relative to lower concentrations, but did not suppress PKA activation to the same extent, likely reflecting the redundancy inherent to many intracellular signalling systems. Moreover, both Gαs and Gαi signalling are known to actively contribute to GCGR effects on hepatic glucose output despite their opposite effects on cAMP, with JNK implicated as a key intermediate in the transduction of Gαs activation in this context [25]. We also observed cholesterol-mediated increases in GCGR internalisation, which is likely to have complex roles in signalling through regulating the availability of surface receptors e.g. via promoting lysosomal degradation, but also in providing a platform for sustained endosomal cAMP generation and engagement with spatially constrained signalling networks not accessible to membrane-resident receptors [40].

There are various mechanisms by which cholesterol and other lipids may alter the stability, ligand binding properties, and thus function of GPCRs [10]: direct competition with agonist binding at the orthosteric site; directly binding at an allosteric site to modulate receptor conformation and dynamics [33]; indirectly via a change in local membrane composition and properties; or a combination of the above e.g. due to interplay between orthosteric and allosteric sites [39]. Recent work has demonstrated that GCGR function can be affected by endogenous allosteric modulators [17,41]. GCGR has computationally predicted potential allosteric cholesterol binding sites, but the validity of these so-called “CRAC” and “CARC” consensus motifs in general has been questioned [42]. Our recently developed MD simulation method to evaluate GPCR-lipid interactions [43] has allowed us to identify probable binding sites for cholesterol on the GCGR, with residence times which differ slightly depending on the receptor state. Site-4, which has the longest cholesterol residence time and lowest Kpps, overlays with the observed binding of a negative allosteric regulator [22] and antagonist [44] in inactive GCGR structures. Cholesterol has been observed to bind to site-4 in the GCGR, with residence times which differ slightly depending on the receptor state. Site-4 has the longest cholesterol residence time and lowest Kpps, overlays with the observed binding of a negative allosteric regulator [22] and antagonist [44] in inactive GCGR structures. Cholesterol has been observed to bind to site-4 in the GCGR, with residence times which differ slightly depending on the receptor state. Site-4, which has the longest cholesterol residue time and lowest Kpps, overlays with the observed binding of a negative allosteric regulator [22] and antagonist [44] in inactive GCGR structures. Cholesterol has been observed to bind to site-4 in the GCGR, with residence times which differ slightly depending on the receptor state. Site-4, which has the longest cholesterol residue time and lowest Kpps, overlays with the observed binding of a negative allosteric regulator [22] and antagonist [44] in inactive GCGR structures. Cholesterol has been observed to bind to site-4 in the GCGR, with residence times which differ slightly depending on the receptor state. Site-4, which has the longest cholesterol residue time and lowest Kpps, overlays with the observed binding of a negative allosteric regulator [22] and antagonist [44] in inactive GCGR structures. Cholesterol has been observed to bind to site-4 in the GCGR, with residence times which differ slightly depending on the receptor state.
biophysical properties may further regulate receptor signalling. For example sites-3/4 are in proximity to previously observed PIP2 binding sites on GCGR [45]. Lipid interplay has been suggested to occur for anionic lipid binding to the ion channel Kir2.2 [46] and warrants further investigation in GPCRs.

An alternative mechanism for GCGR regulation may be receptor redistribution, for example retention intracellularly [47], or into distinct lipid nanodomains. Changes to the pool of accessible cholesterol within sphingomyelin enriched regions [48], for example as a result of diet [49,50], may alter the combination of occupied cholesterol sites. Our observed K\textsubscript{D}’s are within the (patho)-physiological range of membrane cholesterol, rendering differential GCGR partitioning between lipid pools due to changes in cholesterol binding/unbinding physiologically feasible. Using targeted biosensors to measure cAMP production in lipid raft and non-raft membrane region we did not find any evidence that the localisation of cAMP production was preferentially modulated by cholesterol modulating treatments; however, direct monitoring of receptor/effector redistribution would be required to fully investigate this possibility.

GCGR activation causes increased hepatic glucose production and, corresponding with our in vitro study results, we observed that a high cholesterol diet reduced the hyperglycaemic response to a glucagon stimulus in mice, and that this effect was partially reduced by simvastatin treatment. The effect observed was small, possibly due to compensatory mechanisms that make the investigation of glucagon sensitivity challenging in vivo [5]. Supporting this observation however, we observed an increase in surrogate markers of glucagon resistance (fasting serum alanine and glucagon-alanine index) in mice with high hepatic cholesterol, along with relative fasting hypoglycaemia. Glucagon resistance has previously been reported in patients with obesity and NAFLD [3,8] but here we demonstrate glucagon resistance in mice fed a cholesterol-rich diet for just seven days, a period sufficiently short to result in no alteration in body weight nor hepatic fat content. There are intriguing implications of these physiological findings for human health and disease. Statin treatment is associated with increased incidence and worsening of established T2D [51–53], and the degree of low-density lipoprotein-cholesterol (LDL-C) reduction correlates with the likelihood of developing T2D [52]. Genetic polymorphisms of HMGCR and related genes that reduce LDL-C also increase the probability of developing T2D [54,55], whereas patients with monogenic familial hypercholesterolaemia have high levels of hepatic cholesterol and a reduced risk of incident T2D [56,57]. Our data suggest that a reduction in hepatocyte membrane cholesterol may contribute to these effects by increasing sensitivity to the hyperglycaemic effects of physiological glucagon. Our data also potentially reconcile the observations that NAFLD is associated with both an increase in hepatic cholesterol [7,8] and glucagon resistance [5,58]. In NAFLD, glucagon resistance has been proposed to drive impaired glucose tolerance and T2D in a subset of patients. This may be via perturbation of the alpha cell–hepatocyte axis, whereby hepatocytes resistant to glucagon are less able to catabolise circulating amino acids, which causes hypersecretion of glucagon by alpha cells [59]. In this context, hyperglucagonaemia is still capable of increasing glycaemia as glucagon resistance is incomplete. In view of these ostensibly opposite effects on glycaemia that could result from cholesterol-mediated glucagon resistance, further studies are needed to carefully examine which process dominates in different pathological states. Nevertheless, greater understanding of this relationship is likely to underpin new therapies for NAFLD [60].

Antagonising glucagon signalling has long been proposed as a therapeutic strategy for T2D [61]. Our data suggest that cholesterol binding site-4 could be targeted by small molecule allosteric modulators of GCGR activity, as for other GPCRs [62]. Conversely, GCGR agonism is increasingly seen as a viable component of multi-incretin treatment for obesity and diabetes as, when combined with GLP-1R agonism, beneficial effects of glucagon (e.g. amelioration of hepatic steatosis and increased energy expenditure) may be realised without unwanted hyperglycaemia [53]. Our work suggests that it is worth evaluating whether lipid-modifying treatments can increase effectiveness of therapeutic GCGR agonism in metabolic disease.

Our study has limitations. The experimental approaches we used to manipulate cholesterol each have caveats. M\textsubscript{CD} is likely to sequester additional lipids from the plasma membrane [64], which could themselves influence receptor function [45], although our study benefits from using lower M\textsubscript{CD} concentrations than many others (see Supplementary Table 4). Inhibition of HMGCR with statins reduces synthesis of not only cholesterol but also of intermediaries required for post-translational protein modifications including farnesylation and geranylgeranylation [65]. Model lipid membrane experiments confirm that simvastatin decreases the cholesterol content of the membrane [66] but cannot exclude the possibility that they also modify other membrane constituents. Hepatoma cells are convenient for testing proximal GCGR signalling events such as cAMP production and PKA activation, but are not suitable for modelling downstream metabolic responses such as glucose output or β-oxidation. Beyond confirming the effect of simvastatin on glucagon-induced hepatic glucose output from mouse hepatocytes, our manuscript lacks an in-depth evaluation of these phenomena in primary cell models, which is essential to fully understand the implications of the upstream signalling responses observed and should be considered for future work. The dietary changes we implemented in mice altered hepatic cholesterol content, but this is unlikely to have been plasma membrane specific. We also did not check for changes in surface GCGR expression in our in vivo model, and note that this can be reduced by high fat feeding [47]. Despite these caveats, we observed congruent results across different systems that support a role for cholesterol in the regulation of GCGR sensitivity, although it remains possible that different mechanisms underpin our results observed in vitro and in vivo despite them being directionally consistent. Furthermore, it remains unclear whether manipulating the lipid environment of the GCGR influences its signalling properties primarily via a direct effect on receptor function, or by altering the spatial dynamics of GCGR relative to its intracellular effectors; this could be investigated using membrane fractionation techniques, in vitro reconstituted systems, imaging approaches to co-visualise the receptor and its potential interactors, and solid-state NMR experiments at variable cholesterol concentrations.

To conclude, our data suggest that increased hepatocyte membrane cholesterol directly contributes to glucagon resistance and provide a potential molecular basis for this phenomenon.

**ACKNOWLEDGEMENTS**

ERM was supported by a UK Medical Research Council (MRC) Clinical Research Training Fellowship and an Early Career Grant from the Society of Endocrinology while working on this project. TBA is funded by Wellcome (102164/213/2), AT and DC are funded by the MRC (MR/R010676/1 and MC-A654-5GB10, respectively). AT also acknowledges support from Diabetes UK and the European Federation for the study of Diabetes. BJ is supported by the MRC (MR/R010676/1), IPPRF scheme, European Federation for the Study of Diabetes, Society for Endocrinology, British Society for Neuroendocrinology, and the UK National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). TT is funded by the NIHR, the NIHR Imperial BRC and the J.P. Moulton Charitable Foundation. SRB is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 642703 (PREDICT) and by the Academy of Finland (129333, 311466).
REFERENCES

[1] Longuet, C., Sinclair, E.M., Maida, A., Baggio, L.L., Maziarz, M., Charron, M.J., et al., 2008. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metabolism 8(5):359–371.

[2] Penhos, J.C., Wu, C.H., Daunias, J., Reitman, M., Levine, R., 1966. Effect of glucagon on the metabolism of lipids and on urea formation by the perfused rat liver. Diabetes 15(10):740–748.

[3] Suppli, M.P., Bagger, J.J., Lund, A., Demant, M., van Hall, G., Strandberg, C., et al., 2020. Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis. Diabetes 69(6):1090–1099.

[4] Demant, M., Bagger, J.J., Suppli, M.P., Lund, A., Gyldenloev, M., Hansen, K.B., et al., 2018. Determinants of fasting hyperglucagonemia in patients with type 2 diabetes and nondiabetic control subjects. Metabolic Syndrome and Related Disorders 16(10):530–536.

[5] Janah, L., Kjeldsen, S., Galsgaard, K.D., Winther-Sorensen, M., Stojanovska, E., Pedersen, J., et al., 2019. Glucagon receptor signaling and glucagon resistance. International Journal of Molecular Sciences 20(13).

[6] Gar, C., Haschka, S.J., Kern-Matschilles, S., Rauch, B., Sacco, V., Prehn, C., et al., 2021. The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels. Metabolic Syndrome and Related Disorders 16(10):530–536.

[7] Purk, P., Baille, R.A., Wiest, M.M., Mirhahi, F., Choudhury, J., Cheung, O., et al., 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46(4):1081–1090.

[8] Min, H.K., Kapoor, A., Fuchs, M., Mirhahi, F., Zhou, H., Mahler, J., et al., 2012. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metabolism 15(5):665–674.

[9] Thai, D.M., Glukhova, A., Sexton, P.M., Christopoulos, A., 2018. Structural insights into G-protein-coupled receptor allosterism. Nature 559(7712):45–53.

[10] Reiter, E., Ayoub, M.A., Pellissier, L.P., Landoni, F., Musnier, A., Tréfier, A., et al., 2017. β-arrestin signalling and bias in hormone-responsive GPCRs. Molecular and Cellular Endocrinology 440:23–41.

[11] Duncan, A.L., Song, W., Sansom, M.S.P., 2020. Lipid-dependent regulation of ion channels and G protein-coupled receptors: insights from structures and simulations. Annual Review of Pharmacology and Toxicology 60:31–50.

[12] Mahmoud, I., Liu, X., Neya, S., Hoshino, T., 2013. Influence of lipid composition on the structural stability of g-protein-coupled receptor. Chemical & Pharmaceutical Bulletin 61(4):426–437.

[13] Mann, M., Niemela, M., Tynkkynen, J., Javaneinan, M., Kulig, W., Muller, D.J., et al., 2016. Mechanism of allosteric regulation of beta2-adrenergic receptor by cholesterol. Elife 5.

[14] Casiraghi, M., Damian, M., Lescop, E., Poin, E., Moncoq, K., Morellet, N., et al., 2016. Functional modulation of a G protein-coupled receptor conformational landscape in a lipid bilayer. Journal of the American Chemical Society 138(35):11170–11175.

[15] Simons, K., Ikonen, E., 2000. How cells handle cholesterol. Science 290(5497):1721–1726.

[16] Buenaventura, T., Bitsi, S., Laughlin, W.E., Burgoyne, T., Lyu, Z., Oqua, A.I., et al., 2019. Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. PLoS Biology 17(8):e3000997.

[17] McGlone, E.R., Marchanda, J., Jones, B., Pickford, P., Inoue, A., Carling, D., et al., 2021. Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signaling. Molecular Metabolism 53:10126.

[18] Woods, A., Hestlegrave, A.J., Muckett, P.J., Levene, A.P., Clements, M., Mobberley, M., et al., 2011. LKB1 is required for hepatic bile acid transport and canalicul membrane integrity in mice. Biochemical Journal 434(1):49–60.

[19] Tewson, P.H., Martinka, S., Shaner, N.C., Hughes, T.E., Quinn, A.M., 2016. New DAG and cAMP sensors optimized for live-cell assays in automated laboratories. Journal of Biomolecular Screening 21(3):298–305.

[20] Herbst, K.J., Allen, M.D., Zhang, J., 2011. Spatiotemporally regulated protein kinase A activity is a critical regulator of growth factor-stimulated extracellular signal-regulated kinase signaling in PC12 cells. Molecular and Cellular Biology 31(19):4063–4075.

[21] Wan, Q., Okashah, N., Inoue, A., Nehmé, R., Carpenter, B., Tate, C.G., et al., 2016. Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. Journal of Biological Chemistry 293(19):7466–7473.

[22] Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., de Graaf, C., et al., 2017. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature 7:339.

[23] Qiao, A., Han, S., Li, X., Li, Z., Zhao, P., Dai, A., et al., 2020. Structural basis of Gs and Gt recognition by the human glucagon receptor. Science 367(6484):1346–1352.

[24] Gelling, R.W., Du, X.Q., Dickmann, D.S., Romer, J., Huang, H., Cui, L., et al., 2003. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proceedings of the National Academy of Sciences 100(3):1438–1443.

[25] Rossi, M., Zhu, L., McMillin, S.M., Pydi, S.P., Jain, S., Wang, L., et al., 2018. Hepatic G signaling regulates whole-body glucose homeostasis. The Journal of Clinical Investigation 128(2):746–759.

[26] Woods, A., Williams, J.R., Muckett, P.J., Mayer, F.V., Liljedahl, M., Bohlooly, Y.M., et al., 2017. Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Reports 18(3):3043–3051.

[27] Wewer Albrechtensen, N.J., Faerch, K., Jensen, T.M., Witte, D.R., Pedersen, J., Mahendran, Y., et al., 2018. Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotrophic amino acids. Diabetologia 61(3):671–680.

[28] Grady, T., Fickova, M., Tager, H.S., Trivedi, D., Hruby, V.J., 1987. Stimulation of glucagon and glucagonotropic amino acids. Diabetologia 61(3):1443–15520.

[29] Yaojima, M., Hosoda, K., Karabayashi, Y., Nakamura, T., Nagomi, K., Mizushima, Y., et al., 1978. Islets-activating protein (IAP) in Bordetella pertussis that potentiates insulin secretory responses of rats. Purification and characterization. Journal of Biochemistry 83(1):295–303.

[30] Allen, M.D., Zhang, J., 2006. Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters. Biochemical and Biophysical Research Communications 348(2):716–721.

[31] Ansell, T.B., Curran, L., Horrell, M.R., Pipatpolkai, T., Letham, S.C., Song, W., et al., 2021. Relative affinity of protein–cholesterol interactions from equilibrium molecular dynamics simulations. Journal of Chemical Theory and Computation.
Brief Communication

[32] Liang, Y.-L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J., et al., 2017. Phase-plate cryo-EM structure of a class B GPCR–G-protein complex. Nature 546(7656):118–123.

[33] Abiko, I.A., Teixeira, R.D., Engilberge, S., Grahl, A., Grzesiek, S., 2021. Filling of a water-free void explains the allosteric regulation of the β1-adrenergic receptor by cholesterol. bioRxiv, 2021.08.20.457941.

[34] Nehme, R., Carpenter, B., Singhal, A., Strege, A., Edwards, P.C., White, C.F., et al., 2017. Mini-G proteins: novel tools for studying GPCRs in their active conformation. PLoS One 12(4):e0175642.

[35] Jones, B., McGilvray, E.F., Fang, Z., Pickford, P., Correa Jr., I.R., Oishi, A., et al., 2020. Genetic and biased agonist-mediated reductions in beta-arrestin recruitment prolong cAMP signalling at glucagon family receptors. Journal of Biological Chemistry.

[36] Liang, Y., Osborne, M.C., Monia, B.P., Bhanot, S., Gaarde, W.A., Reed, C., et al., 2018. Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. Elife 3.

[37] Levental, K.R., Lorent, J.H., Lin, X., Skinkle, A.D., Surma, M.A., Stockenbojer, E.A., et al., 2015. Novel protein–protein interactions in liver that affect cholesterol homeostasis. Elife 3.

[38] Cheng, C., Jabri, S., Taoka, B.M., Sinz, C.J., 2020. Small molecule glucagon receptor antagonist. Biophysical Journal 119(2):300–313.

[39] Duncan, A.L., Rossmann, M.S., 2020. Defining how multiple lipid species interact with inward rectifier potassium (Kir2) channels. Proceedings of the National Academy of Sciences 117(14):7803–7813.

[40] Charbonneau, A., Melancon, A., Lavoie, C., Lavoie, J.-M., 2005. Altarations in hepatic glucagon receptor density and in Gspalpha and Gialpha2 protein content with diet-induced hepatic steatosis: effects of acute exercise. American Journal of Physiology-Endocrinology and Metabolism 289(1):E8–E14.

[41] Das, A., Brown, M.S., Anderson, D.D., Goldstein, J.L., Radhakrishnan, A., 2014. Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. Elife 3.

[42] Lenvant, K.R., Larent, J.H., Lin, X., Skinkle, A.D., Surma, M.A., Stockenbojer, E.A., et al., 2016. Polyunsaturated lipids regulate membrane domain stability by tuning membrane order. Biophysical Journal 110(8):1800–1810.

[43] Hermetet, F., Buffiere, A., Aznague, A., Pais de Barros, J.P., Bastei, J.N., Delva, L., et al., 2019. High-fat diet disturbs lipid raft/TGF-beta signalling-mediated maintenance of hematopoietic stem cells in mouse bone marrow. Nature Communications 10(1):523.

[44] Danaei, G., Garcia Rodriguez, L.A., Fernandez Cantero, O., Hernan, M.A., 2013. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 36(5):1236–1240.

[45] Wang, S., Cai, R., Yuan, Y., Varghese, Z., Moorhead, J., Ruan, X.Z., 2017. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Scientific Reports 7:39982.

[46] Mansi, I.A., Chansard, M., Lingvay, I., Zhang, S., Halm, E.A., Alvarez, C.A., 2021. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Internal Medicine.

[47] Swerdlow, D.I., Preiss, D., Kuchenbaecker, K.B., Holmes, M.V., Engmann, J.E., Shah, T., et al., 2015. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385(9965):351–361.

[48] Lotta, L.A., Sharp, S.J., Burgess, S., Perry, J.R.B., Stewart, I.D., Willems, S.M., et al., 2016. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 316(13):1383–1391.

[49] Besseling, J., Kastelein, J.J., Defesche, J.C., Hutton, B.A., Hovingh, G.K., 2015. Association between familial hypercholesterolaemia and prevalence of type 2 diabetes mellitus. JAMA 313(10):1029–1036.

[50] Hoeg, J.M., Demosky Jr., S.J., Schaefer, E.J., Starzl, T.E., Brewer Jr., H.B., 1984. Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemia-emic subjects. Journal of Clinical Investigation 73(2):429–436.

[51] Albrechtsen, N.J.W., Junker, A.E., Christensen, M., Haedersdal, S., Wibrand, F., Lund, A.M., et al., 2018. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. American Journal of Physiology - Gastrointestinal and Liver Physiology 314(1):E91–G96.

[52] Holst, J.J., Wewer Albrechtsen, N.J., Pedersen, J., Knap, F.K., 2017. Glucagon and amino acids are linked in a mutual feedback cycle: the liver-x-axis. Diabetes 66(2):235–240.

[53] Younossi, Z.M., Stepanova, M., Ono, J., Trimble, G., AlAhtani, S., Younossi, I., et al., 2021. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clinical Gastroenterology and Hepatology 19(3):580–589 e585.

[54] Cheng, C., Jabri, S., Taoka, B.M., Sinz, C.J., 2020. Small molecule glucagon receptor antagonists: an updated patent review (2015–2019). Expert Opinion on Therapeutic Patents 30(7):509–526.

[55] Lu, J., Byrne, N., Wang, J., Bricogne, G., Brown, F.K., Chobanian, H.R., et al., 2017. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPRA0. Nature Structural & Molecular Biology 24(7):570–577.

[56] Ambrey, P., Parker, V.E., Stumvoll, M., Posch, M.G., Heise, T., Plum-Moerschel, L., et al., 2018. MED10382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 391(10140):267–2618.

[57] Zidovetzki, R., Levitan, I., 2007. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochimica et Biophysica Acta 1768(6):1311–1324.

[58] Werner, N., Nickenberg, G., Lauts, U., 2002. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Research in Cardiology 97(2):105–116.

[59] Barthkowiak, A., Matyszewska, D., Krzak, A., Zabrowska, M., Broniatowski, M., Bilewicz, R., 2021. Incorporation of simvastatin into lipid membranes: why deliver a statin in form of inclusion complex with hydrophilic cyclodextrin. Colloids and Surfaces B: Biointerfaces 204:111784.